Table 1 Clinico-pathological characteristics of the 114 patients with primary cutaneous melanoma.

From: A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants

Characteristic

Group

N (%)

Sex

Male

69 (60.5%)

Female

45 (39.5%)

Age range: 24–93

≤66

58 (50.9%)

(mean/median = 62/66 years)

>66

56 (49.1%)

Classification (tumor stage)

pT1 (≤1 mm)

5 (4.4%)

pT2 (>1–2 mm)

23 (20.2%)

pT3 (>2–4 mm)

48 (42.1%)

pT4 (>4 mm)

38 (33.3%)

Location

Head

10 (8.8%)

Trunk

69 (60.5%)

Upper extremities

17 (14.9%)

Lower extremities

18 (15.8%)

Histological subtype

SSM

68 (59.6%)

NM

46 (40.4%)

Ulceration

No

60 (52.6%)

Yes

54 (47.4%)

Regression

No

93 (81.6%)

Yes

21 (18.4%)

Sentinel nodes

No

43 (37.7%)

Yes

71 (62.3%) - 19 positive (26.7%)

TILs†

Absent

7 (9.5%)

(scoring system by Clark)

Non-brisk

50 (67.5%)

 

Brisk

17 (23.0%)

Death due to melanoma‡

No

71 (67.6%)

§mean/median DFS = 34/24 months

Yes

34 (32.4%)

Local recurrence‡

No

88 (83.8%)

§mean/median LFS = 22/10 months

Yes

17 (16.2%)

Metastasis‡

No

81 (77.1%)

§mean/median MFS = 25/18 months

Yes

24 (22.9%)

  1. †Information is missing for several cases, ‡data is based on 105 cases without targeted therapy. §Mean and median of months was calculated only for cases with respective events. DFS – disease-free survival, LFS – local recurrence-free survival, MFS – metastasis-free survival, NM – nodular melanoma, SSM - superficial spreading melanoma, TIL – tumor infiltrating lymphocytes. TILs were assessed using the scoring system by Clark as described elsewhere46.
Back to article page